Caricamento...
Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer
BACKGROUND: Small cell lung cancer (SCLC) is a recalcitrant malignancy with distinct biologic properties. Antibody targeting therapy has been actively investigated as a new drug modality. METHODS: We tested the expression of IGF-1R and calculated the survival in 61 SCLC patients. We also evaluated t...
Salvato in:
| Pubblicato in: | PLoS One |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Public Library of Science
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4545894/ https://ncbi.nlm.nih.gov/pubmed/26287334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0135844 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|